Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Product Parachute? Firm Could See Rally Around New Approvals

You may also be interested in...



Congress has faith in Pfizer

Pfizer was the pharmaceutical sector stock most widely held by members of the House and Senate in 2005 and the second-most widely held stock overall by Congress, according to the Center for Responsive Politics. Pfizer's stock dropped nearly 15% in 2005 (1"The Pink Sheet" Jan. 30, 2006, p. 27). The review found 32 Democrats and 47 Republicans held shares in Pfizer. Other widely held pharma sector stocks include Johnson & Johnson (number 7 overall), Procter & Gamble (8), Merck (16) and Amgen (18)...

Congress has faith in Pfizer

Pfizer was the pharmaceutical sector stock most widely held by members of the House and Senate in 2005 and the second-most widely held stock overall by Congress, according to the Center for Responsive Politics. Pfizer's stock dropped nearly 15% in 2005 (1"The Pink Sheet" Jan. 30, 2006, p. 27). The review found 32 Democrats and 47 Republicans held shares in Pfizer. Other widely held pharma sector stocks include Johnson & Johnson (number 7 overall), Procter & Gamble (8), Merck (16) and Amgen (18)...

“One Pfizer” Restructuring Initiative Divides R&D And Sales Operations

Pfizer's latest corporate restructuring represents a shift away from its recent alignment of research & development and commercialization operations

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel